Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 5 of 25
Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV
NCT02560805
Sympatholysis in Chronic Kidney Disease
NCT02411773
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
NCT02447874
Sympathetic Overactivity in Post-traumatic Stress Disorder
NCT01627301
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
NCT00601939
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development
NCT00243776
Cardiology Biobank Registry
NCT00378924
Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria
NCT01659749
Systems Biological Analysis of Immune Responses to RSV Vaccine
NCT07185399
I Can Do This! Managing My Diabetes
NCT06695533
Father-Inclusive Parenting Intervention in Mwanza, Tanzania
NCT07025447
Immunology of Ebola Vaccine
NCT06100913
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
NCT06295458
Testing an Integrated Care Model Trial
NCT06448429
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
NCT06205368
CGM and DFU Healing Post-discharge
NCT06054659
Suture Closure Trial
NCT05261425
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
NCT06105918
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
NCT06328699
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
NCT05798507
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
NCT05779943
PRogram to Improve Stress-levels and Enhance Memory
NCT05845918
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
NCT05384847
The Precision CAD Trial
NCT04755413
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
NCT05391750
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
NCT05341349
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
NCT05387915
RElugolix VErsus LeUprolide Cardiac Trial
NCT05320406
Natural Progesterone for the Treatment of Recurrent Glioblastoma
NCT05091866
Prevention of NAFLD in Hispanic Children
NCT05292352
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT05245682
Assessing Durable Antibody Response to HPV Vaccination
NCT05031078
Abatacept Conversion in Kidney Transplantation
NCT04955366
Radiosurgery Before Surgery for the Treatment of Brain Metastases
NCT04895592
Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer
NCT04780477
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04754945
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
NCT04731376
Cross-disciplinary HIV Integrated Mental Health Support Intervention
NCT04833829
Oral Anti Diabetic Agents in the Hospital
NCT04416269
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
NCT04393350
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
NCT04340882
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
NCT03983993
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
NCT03924401
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
NCT04022343
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT03942224
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT03719131
Rifaximin in Patients With Monoclonal Gammopathy
NCT03820817
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
NCT03762759
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
NCT03872180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.